Core Insights - Recent market style has shifted, with growth assets experiencing a "pain period" as sectors like electronics and biopharmaceuticals have seen significant declines since October [1] - The current adjustment in the dual innovation sector is attributed to structural differentiation within the market, where previous substantial gains have led to elevated valuation levels, setting the stage for a correction [1] - Short-term corrections are viewed as healthy adjustments following rapid increases, with the PE ratio of the Sci-Tech Innovation 50 Index dropping from 67 times on October 9 to 57 times on October 31, indicating a valuation repair that could build momentum for the next market phase [1] - Positive catalysts are emerging both domestically and internationally, including policy support emphasizing "technological self-reliance," potential expansion of domestic monetary policy easing, and the rapid rise of emerging industries such as artificial intelligence, semiconductors, and innovative pharmaceuticals [1] Investment Opportunities - The Sci-Tech Innovation 50 ETF (588080), the Growth Enterprise Board ETF (159915), and the Sci-Tech Innovation and Growth ETF (159781) are leading in scale among their tracked indices, offering good liquidity and a management fee rate of 0.15% per year, making them convenient options for investors looking to capitalize on "Sci-Tech + Growth" opportunities [2]
双创板块震荡调整现布局良机,关注科创板50ETF(588080)、创业板ETF(159915)等产品配置价值